The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma by LaurenEBS | Feb 13, 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database by LaurenEBS | Feb 13, 2021
